Aelis Farma SA (AELIS) AI Stock Analysis

Aelis Farma SA

(Paris:AELIS)

Select Model

Rating:38Underperform

Price Target:EUR 0.70▼(-3.87% Downside)

Action:reiterated

Date:10/30/26

The score is driven primarily by severe revenue contraction, ongoing losses, equity erosion, and cash burn. Bearish technical trends and a negative P/E provide little offset, resulting in a very weak overall stock profile.

Positive Factors

Focused therapeutic platformA focused platform around endocannabinoid-system modulation gives Aelis a clearly defined scientific direction and potential to build expertise across related neurological and peripheral indications. Its lead program targets cannabis use disorder through a differentiated mechanism intended to reduce THC effects while preserving normal signaling.

Negative Factors

Declining and volatile revenueFalling and volatile revenue indicates that the current business base is not yet providing a dependable platform for funding operations. Revenue well below 2023 levels makes recovery dependent on future commercialization or development progress, increasing uncertainty around the path to sustainable growth.

Aelis Farma SA (AELIS) vs. iShares MSCI France ETF (EWQ)

Market Cap: EUR 9.86M
Dividend Yield: ―
Average Volume (3M): 15.56K
Price to Earnings (P/E): -2.2
Beta (1Y): 0.65
Revenue Growth: -97.09%
EPS Growth: 45.00%
Country: France
Employees: 14
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Aelis Farma SA Business Overview & Revenue Model

Company Description

Aelis Farma S.A., a French biotechnology company founded in 2013 and headquartered in Bordeaux, is dedicated to the discovery and development of treatments for brain-related illnesses. The firm's research pipeline primarily focuses on signaling-speci...

Aelis Farma SA Financial Statement Overview

Summary

Severe financial weakness: revenue fell to €2.1M, net losses widened to €6.4M, equity declined to €4.4M, and operating cash flow remained negative at -€5.4M. Debt increased to €6.6M, leaving significant funding and execution risks.

Income Statement

25Negative

Balance Sheet

45Neutral

Cash Flow

20Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.64M	2.08M	2.68M	9.05M	3.81M	9.07M
Gross Profit	-3.10M	-279.00K	2.68M	9.05M	3.81M	9.07M
EBITDA	-7.08M	-8.00M	-7.18M	-6.35M	-16.23M	844.00K
Net Income	-4.52M	-6.43M	-7.46M	-5.08M	-14.29M	574.00K
Balance Sheet
Total Assets	8.44M	12.05M	19.71M	26.28M	39.22M	28.31M
Cash, Cash Equivalents and Short-Term Investments	6.62M	8.21M	14.05M	20.23M	34.40M	24.71M
Total Debt	4.38M	6.60M	6.25M	4.04M	3.82M	6.41M
Total Liabilities	6.12M	7.61M	9.59M	13.08M	19.43M	27.41M
Stockholders Equity	2.31M	4.44M	10.12M	13.20M	19.79M	899.00K
Cash Flow
Free Cash Flow	-3.48M	-5.39M	-11.72M	-12.67M	-13.19M	18.76M
Operating Cash Flow	-3.48M	-5.38M	-11.53M	-12.59M	-13.05M	18.97M
Investing Cash Flow	-837.00K	-841.00K	-190.00K	-88.00K	-86.00K	-212.00K
Financing Cash Flow	-703.00K	538.00K	5.81M	-1.34M	22.10M	180.00K

Aelis Farma SA Technical Analysis

Technical Analysis SentimentNegative

Last Price0.72

Price Trends

50DMA0.87Negative

100DMA0.96Negative

200DMA1.13Negative

Market Momentum

MACD-0.05Negative

RSI38.98Neutral

STOCH65.77Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:AELIS, the sentiment is Negative. The current price of 0.72 is below the 20-day moving average (MA) of 0.74, below the 50-day MA of 0.87, and below the 200-day MA of 1.13, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 38.98 is Neutral, neither overbought nor oversold. The STOCH value of 65.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:AELIS.

Aelis Farma SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

FR:AELIS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:POXEL	46Neutral	EUR 8.87M	-0.43	33.88%	―	―	―
FR:SIGHT	43Neutral	EUR 18.98M	-1.06	52.39%	―	-610.31%	43.88%
FR:ALBPS	42Neutral	EUR 11.52M	-0.01	153.48%	―	―	90.97%
FR:ALDVI	38Underperform	EUR 9.42M	217.14	-0.18%	―	0.10%	99.69%
FR:AELIS	38Underperform	EUR 9.91M	-2.19	―	―	-97.09%	45.00%

* Healthcare Sector Average

Performance Comparison

FR:AELIS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
FR:AELIS	Aelis Farma SA	0.72	-0.41	-36.02%
FR:POXEL	Poxel SA	0.17	-0.17	-50.30%
FR:SIGHT	GenSight Biologics	0.08	-0.05	-38.89%
FR:ALDVI	Advicenne SA	0.65	-1.05	-61.99%
FR:ALBPS	Biophytis SA	0.03	-0.08	-71.70%
FR:ALNFL	NFL Biosciences SA	0.45	-0.70	-60.73%

Aelis Farma SA Corporate Events

Aelis Farma Publishes 2026 Half-Year Financial Report

Sep 24, 2026

Aelis Farma announced that its 2026 half-year financial report has been filed with the French Financial Markets Authority and is now available to the public on the company’s website. The publication offers investors and stakeholders updated vis...

Aelis Farma Secures Key EMA Backing and Extends Cash Runway as CB1 Pipeline Advances

Sep 15, 2026

In the first half of 2026, Aelis Farma advanced its clinical priorities, most notably the international Phase 2b trial of AEF0217 in people with Down syndrome, with recruitment on track and a positive safety committee recommendation. A key regulatory...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026

Aelis Farma SA AI Stock Analysis